Skip to main content
Loading

Potency and safety considerations for iPSC-derived cell products

25 Sep 2024
Monterey
Cell Therapy Development
  • What are the advantages and challenges for allogeneic vs autologous iPSC-derived product?
  • How should we determine appropriate genomic integrity assessment from end to end process?
  • What new analytical methods could improve our ability to characterize identified CQA?
  • Is this critical to have fully matured cells (terminally differentiated cells) as a product?
Industry Expert
Lina Sui, Senior Director - Sana Biotechnology